Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival

被引:0
|
作者
Wang, Zhaoxi [1 ]
Choi, Sojung [2 ]
Lee, Jinseon [2 ]
Huang, Yen-Tsung [5 ]
Chen, Feng [3 ]
Zhao, Yang [3 ]
Lin, Xihong [4 ]
Neuberg, Donna [4 ]
Kim, Jhingook [2 ]
Christiani, David C. [2 ]
机构
[1] Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA
[2] Samsung Med Ctr, Dept Thorac Surg, Seoul, South Korea
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[4] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA
[5] Brown Univ, Providence, RI 02912 USA
来源
CANCER INFORMATICS | 2015年 / 14卷
关键词
mitochondria genome; mitochondria mutations; lung cancer survival; haplogroup; mitochondrial genome resequencing;
D O I
10.4137/CIn.s13976
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the mtDNA genome have long been suspected to play an important role in cancer. Although most cancer cells harbor mtDNA mutations, the question of whether such mutations are associated with clinical prognosis of lung cancer remains unclear. We resequenced the entire mitochondrial genomes of tumor tissue from a population of 250 Korean patients with non-small cell lung cancer (NSCLC). Our analysis revealed that the haplogroup (D/D4) was associated with worse overall survival (OS) of early-stage NSCLC [adjusted hazard ratio (AHR), 1.95; 95% CI, 1.14-3.33; P-trend = 0.03]. By comparing the mtDNA variations between NSCLC tissues and matched blood samples, we found that haplogroups M/N and/or D/D4 were hotspots for somatic mutations, suggesting a more complicated mechanism of mtDNA somatic mutations other than the commonly accepted mechanism of sequential accumulation of mtDNA mutations.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [31] Staging of non-small cell lung cancer (NSCLC): A review
    Tsim, S.
    O'Dowd, C. A.
    Milroy, R.
    Davidson, S.
    [J]. RESPIRATORY MEDICINE, 2010, 104 (12) : 1767 - 1774
  • [32] Induction therapy for non-small cell lung cancer (NSCLC)
    Nakamura, H
    Furukawa, K
    Ikeda, N
    Shibuya, H
    Tanaka, K
    Okunaka, T
    Hirano, T
    Sakai, M
    Saito, M
    Konaka, C
    Kato, H
    [J]. XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, : 1029 - 1033
  • [33] Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
    Gadgeel, Shirish M.
    [J]. LUNG CANCER AND PERSONALIZED MEDICINE: NOVEL THERAPIES AND CLINICAL MANAGEMENT, 2016, 890 : 203 - 222
  • [34] Survival pattern of non-metastatic non-small cell lung cancer (NSCLC) in the United States
    Meshref, A.
    Mousa, M.
    Ramadan, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [35] Immune Cell Profiles as Predictors of Survival in Surgically Treated Non-Small Cell Lung Cancer (NSCLC)
    Sellmer, L.
    Kovacs, J.
    Neumann, J.
    Walter, J.
    Kauffmann-Guerrero, D.
    Syunyaeva, Z.
    Fertmann, J.
    Schneider, C.
    Zimmermann, J.
    Behr, J.
    Tufman, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S910 - S910
  • [36] STAGE DISTRIBUTION AT DIAGNOSIS OF NON-SMALL CELL LUNG CANCER (NSCLC) AND GEOGRAPHIC VARIATION IN SURVIVAL
    Chikermane, S.
    Johnson, M. L.
    [J]. VALUE IN HEALTH, 2019, 22 : S58 - S58
  • [37] Potential surrogates for performance status and survival in metastatic non-small cell lung cancer (NSCLC)
    Akerley, Wallace L.
    Puri, Sonam
    Jo, Yeonjung
    Coletta, Adriana M.
    Kerrigan, Kathleen Claire
    Patel, Shiven B.
    Moynahan, Kelly
    Cannon, Laura
    Gumbleton, Matthew
    Hillman, Nicole
    Embrey, Kelsey
    Haaland, Benjamin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [38] Survival impact of aggressive treatment on patients with oligometastatic non-small cell lung cancer (NSCLC).
    Gauvin, Camille
    Blais, Normand
    Tehfe, Mustapha
    Florescu, Marie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Differential expression of angiogenic and of vascular survival factors in non-small cell lung cancer (NSCLC)
    Giatromanolaki, A
    [J]. ANGIOGENESIS: FROM THE MOLECULAR TO INTEGRATIVE PHARMACOLOGY, 2000, 476 : 291 - 295
  • [40] QUANTITATIVE MODELING AND SURVIVAL ANALYSIS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS.
    Lee, T.
    Cao, Y.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S29 - S29